Table 3. Summary of survival.
| Summary of survival | Survival since Y-90 treatment, months (n=15) |
Survival since diagnosis, months (n=15) |
|||
|---|---|---|---|---|---|
| Median | Range | Median | Range | ||
| Overall | 8.4 | 1.3-21.1 | 11.7 | 3.4-43.2 | |
| Treatment modality | |||||
| TheraSpheres | 8.4 | 1.3-21.1 | 11.7 | 3.4-43.2 | |
| SIR-Spheres | 7.8 | 2.3-12.5 | 9.9 | 3.8-19.4 | |
| Child-Pugh | |||||
| A (n=7) | 8.8 | 2.27-21.1 | 11.7 | 5.2-43.2 | |
| B (n=7) | 8.4 | 3.0-19.2 | 13.7 | 3.8-36.1 | |
| C (n=1) | 1.3 | 3.4 | |||
| BCLC staging | |||||
| A (n=1) | 12.5 | 14.5 | |||
| B (n=10) | 9.7 | 2.3-21.1 | 15.1 | 5.2-43.2 | |
| C (n=3) | 3 | 2.3-5.7 | 7.1 | 3.8-11.4 | |
| D (n=1) | 1.3 | 3.4 | |||
Y-90, Yttrium-90; BCLC staging, Barcelona Clinic Liver Cancer staging.